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The chemotactic activities of neutrophil granulocytes 
of patients with pustular and vulgar psoriasis were eval-
uated before and after treatment with etretinate. Con-
trol values before treatment were significantly different 
from those of vulgar psoriasis group but not from the 
pustular psoriasis group. The difference between the 2 
groups with psoriasis was significant. Etretinate causes 
a significant reduction in neutrophil chemotaxis in pus-
tular psoriasis patients and a less pronounced reduction 
in those with vulgar psoriasis. 
The therapeutic effectiveness of etretinate for psoriasis is 
now known and widely accepted [1]. It is the rapid effectiveness 
of the drug in von Zumbusch's generalized pustular psoriasis 
(PP) that is of special interest to dermatologists. In vulgar 
psoriasis (VP), and in particular in its pustular form, there ;s 
a conspicuous infiltration of neutrophil granulocytes into the 
epidermis. Some authors [2-6] maintain that there is increased 
neutrophil chemotaxis in psoriasis, whereas' others have not 
found this to be so. 
The aim of our study was to evaluate the chemotactic activ-
ities of the neutrophil granu locytes in patients with PP and 
VP, before and after treatment with etretinate for 15 days. 
MATERIALS AND METHODS 
Patients 
We studied 10 patients with von Zumbusch's generalized PP (7 men 
and 3 women, aged 18- 68, average age 47); 10 patients with generalized 
VP, in patches covering more than 50% of the body surface area (8 
men and 2 women, aged 28-60, average age 51). All the patients were 
hospitalized for treatment of psoriasis. They gave written consent to 
take part in the investigation. 
Biopsies were taken from most of these patients to confirm the 
clinical diagnosis. The controls were 60 healthy normal subjects (19-
54, average age 41). None of the patients had any other disease. A 
venous blood sample was taken from each subject at the beginning of 
the study and another sample was taken after 2 weeks of treatment 
from the patients with psoriasis. 
Materials 
The aromatic retinoid etretinate (Ro-10 9359), kindly supplied by 
Hoffmann-La Roche, was administered for 15 days, in a dose of 1 mg 
per kg body weight, as a single dai ly administration after a lipid-rich 
meal. 
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Abbreviations: 
PMN: polymorphonuclear 
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Polymorphonuclear Leulwcyte Preparation 
Polymorphonuclear (PMN) leukocytes were isolated by a modifica-
t ion of the method of Maderazo and Woronick [7] . The PMN leuko-
cytes were adjusted to a concentration of 2 x 106 cells per ml medium. 
The fina l cell preparation contained more than 90% neutrophils, with 
viability greater than 95% as assessed by trypan blue exclusion. 
Preparation of Chemotactic Factor 
Normal human serum was incubated with 5 mg/m l Zymosan (Sigma 
Chemical Co.) in a 37•c water bath for 30 min. The activated serum 
was centrifuged (10 min, 700 g) and stored frozen in liquid nitrogen. 
Chemotaxis Assay 
This was studied in vitro by the Boyden method [8], as modified by 
Siccardi [9] . A two-section chamber (LP Italiana S.p.A., Milano) , with 
the sections separated by a Millipore filter with 3-J.Lm pores, was used. 
The PMN leukocytes were placed in the upper section and the culture 
medium, RPMI 1640 with or without chemotactic factor , in the lower 
section. The chambers were incubated for 1.5 h at 37·c. The fi lters 
were removed, fixed with methanol , stained with hematoxylin, and 
mounted on glass slides. All assays were run in duplicate. 
To measure leukocyte mobility, the "leading front" technique was 
chosen, and the values, expressed in J.Lm , are the differences between 
chemotactic and random migration in the distance covered by the 2 
fastest cells in 10 microscopic fie lds. 
Statistical Analysis 
The biologic results were analyzed by the Student t-test for paired 
and unpaired data. 
RESULTS 
As listed in Table I, random migration did not differ from 
the normal in any group before or after treatment. Neutrophil 
granulocytes in healthy subjects have chemotactic activities 
which are midway between those of patients with.PP and those 
with VP. 
The control values were significantly different from the VP 
group (p < 0.01) but were not different from the PP group. 
Furthermore, the difference between the 2 groups with psoriasis 
was significant before treatment (p < 0.0005). 
It can be observed that after 14 days of treatment with 
etretinate, the chemotactic values are significantly lower in PP 
(p < 0.0005) and less pronounced in VP (p < 0.005) . The 
chemotactic values after treatment were rather similar. 
DISCUSSION 
Our data provide new insight into the intricate field of 
evaluation of neutrophil chemotaxis in psoriasis. Our data 
support the division of patients with psoriasis into 2 groups, 
those with PP and those with VP. In the first group, chemo-
tactic activity appears to be slightly greater than that encoun-
tered in healthy control subjects, whereas in the VP group it is 
less. Although only VP chemotactic activity differs significantly 
from the normal, the chemotactic activities of PP and VP differ 
significantly from each other (p < 0.0005) . 
Treatment with etretinate brings about a dramatic reduction 
of chemotaxis, especially in the group of patients with PP who 
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TABLE I. Random and chemotactic activities of neutrophil granulocytes pre- and posttreatment with etretinate in patients with pu.stular and 
vulgar psoriasis 
Pretreatment (pre· T) Posttreatment (post-T)" 
Chemotactic (C)' Random (R) Group No. Random (R) Chemo
tactic (C)' 
Mean ± SO (range) Mean ± SO (range) Mean ± SO (range) Mean ± SO (range) 
Controls (C) 60 18.7 ± 3.7< 82.3 ± 11 
(11- 26) (65- 110) 
Pustular psorias is (PP) 10 18.2 ± 3.1< 89.2 ± 6.9 17.9 ± 4.8< 57±17.9 
(15- 23) (73- 98) (8-22) (16- 78) 
Vulgar psorias is (VP) 10 18.1 ± 2.3< 74 ± 6.5 18.3 ± 2.3< 64.6 ± 6.5 
(14- 21) (65-88) (15-22 ) (53-76) 
PP pre-T C vs C not s ignificant PP pre-T C vs PP post-T C p < 0.0005 
p < 0.005 VP pre-T C vs C p < O.Ql VP pre-T C vs VP post-T C 
PP pre-T C vs VP pre-T C p < 0.0005 PP post-T C vs VP post-T C not s ignificant 
"After 15 days of etretinate, 1 mg/kg body weight per day. 
1
' All t he activitie are in I'm; chemotactic activities are the difference between total and random migration. 
<Values of random migration do not differ from the normal in all t he groups before and after treatment. 
have high values to begin with, but also in those with VP. It 
could be hypothesized that the antigens of the stratum cor-
neum, immunocomplexes linked to the tissues, and the physi-
ologic chemoattractors (epidermis and proteolytic enzymes, 
auto-antibodies against the stratum corneum, factors of blood 
complement metabolites derived from arachidonic acid) (10-
16] are all eliminated by exfoliation and that more of these 
substances are present in PP than in VP. On the other hand, 
it might also be that etretinate acts directly on the PMN cells 
to inhibit their diapedetic activity. 
This inhibition is greater in PP, in which PMN leukocytes 
play a major role. It also agrees with the microscopically ob-
served intravenous blocking of neutrophil granulocytes [17,18] 
in retinoid-treated PP, which is not perceptible in the vulgar 
variety. 
This concurrence of theory with clinical, histologic , and 
laboratory data, may offer a clue to the drug's mechanism of 
action. The laboratory data, agree with the dramatic effects of 
the retinoids in therapy of PP, and explain the good but lesser 
activity in the vulgar form. The cellular and biochemical aspects 
of the decrease in chemotactic activity need further study. 
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